SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

PVLA

Palvella Therapeutics Inc.
NEUTRAL
Impact 6/10
Horizonmonths Processed11d 19h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The NDA acceptance with Priority Review is the primary catalyst, with a clear PDUFA date in February 2027. Monitor for any FDA advisory committee meeting announcements and the company's commercial launch preparations. The expanding pipeline (new indications and product candidate expected by year-end) could provide additional upside if positive data emerges.

DirectionNeutral
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

Palvella reported Q3 2026 net loss of $24.6M ($1.70/share), wider than the $11.3M loss in Q3 2025, driven by increased R&D and G&A spending. The key event is the FDA's acceptance of the NDA for QTORIN rapamycin in microcystic lymphatic malformations with Priority Review and a PDUFA date of February 28, 2027, bringing the company closer to a potential first FDA-approved therapy for this indication.

Key Financial Metrics

EPS
−$1.70

Key Facts

  • FDA accepted NDA for QTORIN rapamycin in microcystic lymphatic malformations with Priority Review; PDUFA target action date February 28, 2027
  • Q3 2026 net loss $24.6M ($1.70/share) vs $11.3M ($1.03/share) in Q3 2025
  • Cash, cash equivalents and short-term investments of $236.7M as of September 30, 2026
  • R&D expenses $10.8M in Q3 2026 vs $6.5M in Q3 2025; G&A expenses $11.9M vs $3.6M
  • Phase 3 trial for cutaneous venous malformations on track for Q4 2026 initiation
  • Topline results from LOTU Phase 2 trial for angiokeratomas expected H2 2027
  • Phase 2 trial for DSAP expected to initiate in Q4 2026
  • Company plans to announce fourth QTORIN rapamycin indication and third product candidate in Q4 2026

Financial Impact

Net loss widened by $13.3M YoY; cash position $236.7M provides runway through potential launch

net losscash positionR&D expenseG&A expense

Risk Factors

  • FDA may not approve the NDA by the PDUFA date or may require additional data
  • Commercial launch execution risk if approved, as the company has no prior commercial experience
  • Widening losses and increasing operating expenses could pressure cash runway if approval is delayed
  • Clinical trial failures in other pipeline programs could negatively impact sentiment

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3396310

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 Viewing No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 6h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026